

# Dagmar Koethe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6379082/publications.pdf>

Version: 2024-02-01

57  
papers

5,041  
citations

126858

33  
h-index

175177

52  
g-index

60  
all docs

60  
docs citations

60  
times ranked

5673  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and <i>N</i> -Acylethanolamines by Liquid Chromatography-Tandem Mass Spectrometry. <i>Cannabis and Cannabinoid Research</i> , 2023, 8, 657-669.	1.5	5
2	Neural Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-Episode Psychosis, and Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2021, 12, 654602.	1.3	19
3	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. <i>Frontiers in Pharmacology</i> , 2021, 12, 614811.	1.6	24
4	Neurobiology Youth Follow-up Study: protocol to establish a longitudinal and prospective research database using multimodal assessments for current and past mental health treatment-seeking young people within an early intervention service. <i>BMJ Open</i> , 2021, 11, e044731.	0.8	1
5	Cannabis use and psychosis: a review of reviews. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 403-412.	1.8	123
6	Early intervention, prevention, and prediction in mood disorders: Tracking multidimensional outcomes in young people presenting for mental health care. , 2020, , 39-62.		4
7	Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. <i>Current Opinion in Psychiatry</i> , 2020, 33, 20-42.	3.1	42
8	Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. <i>Frontiers in Psychiatry</i> , 2020, 11, 576877.	1.3	20
9	Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services. <i>BMJ Open</i> , 2020, 10, e035379.	0.8	5
10	Right care, first time: a highly personalised and measurement-based care model to manage youth mental health. <i>Medical Journal of Australia</i> , 2019, 211, S3-S46.	0.8	88
11	Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 897-910.	1.8	2
12	Familial abnormalities of endocannabinoid signaling in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 117-125.	1.3	26
13	Cannabiskonsum zum Freizeitgebrauch. , 2019, , 65-264.		1
14	Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. <i>CNS Drugs</i> , 2018, 32, 605-619.	2.7	36
15	Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages. <i>ELife</i> , 2018, 7, .	2.8	92
16	570. Differential Association of Anandamide Levels with Binocular Depth Inversion Illusion Scores in Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S230-S231.	0.7	0
17	Association of anandamide with altered binocular depth inversion illusion in schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 483-488.	1.3	22
18	Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. <i>American Journal on Addictions</i> , 2014, 23, 308-312.	1.3	31

#	ARTICLE	IF	CITATIONS
19	Identification of a Molecular Profile Associated with Immune Status in First-Onset Schizophrenia Patients. <i>Clinical Schizophrenia and Related Psychoses</i> , 2014, 7, 207-215.	1.4	30
20	Source-Reconstruction of Event-Related Fields Reveals Hyperfunction and Hypofunction of Cortical Circuits in Antipsychotic-Naive, First-Episode Schizophrenia Patients during Mooney Face Processing. <i>Journal of Neuroscience</i> , 2014, 34, 5909-5917.	1.7	58
21	Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 459-463.	1.8	66
22	Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. <i>NeuroImage</i> , 2013, 79, 304-312.	2.1	93
23	Evidence for dysregulated high-frequency oscillations during sensory processing in medication-naïve, first episode schizophrenia. <i>Schizophrenia Research</i> , 2013, 150, 519-525.	1.1	86
24	A TWIN STUDY ON ABNORMALITIES OF ENDOCANNABINOID FUNCTIONING IN SCHIZOPHRENIA AND BIPOLAR DISORDER. <i>Schizophrenia Research</i> , 2012, 136, S26-S27.	1.1	0
25	Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. <i>Translational Psychiatry</i> , 2012, 2, e94-e94.	2.4	787
26	Identification of a biological signature for schizophrenia in serum. <i>Molecular Psychiatry</i> , 2012, 17, 494-502.	4.1	189
27	Alterations of primary fatty acid amides in serum of patients with severe mental illness. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 308-314.	0.9	12
28	Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naïve schizophrenia patients. <i>Molecular Psychiatry</i> , 2011, 16, 848-859.	4.1	81
29	Cerebrospinal fluid diagnostics in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 529-530.	1.8	18
30	Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. <i>Proteomics</i> , 2011, 11, 94-105.	1.3	76
31	Improvement of General Symptoms in a Chronic Psychotic Patient Treated with Finasteride: Case Report. <i>Pharmacopsychiatry</i> , 2011, 44, 163-163.	1.7	0
32	Differential effects on T-cell function following exposure to serum from schizophrenia smokers. <i>Molecular Psychiatry</i> , 2010, 15, 364-371.	4.1	12
33	Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. <i>Molecular Psychiatry</i> , 2010, 15, 1088-1100.	4.1	108
34	Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. <i>Molecular Psychiatry</i> , 2010, 15, 118-119.	4.1	129
35	Validation of a Blood-Based Laboratory Test to Aid in the Confirmation of a Diagnosis of Schizophrenia. <i>Biomarker Insights</i> , 2010, 5, BMI.S4877.	1.0	137
36	Familial Differential Treatment Response in Schizophrenia – Lessons From a Case of Three Affected Siblings. <i>Pharmacopsychiatry</i> , 2010, 43, 196-197.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. <i>British Journal of Psychiatry</i> , 2009, 194, 371-372.	1.7	157
38	Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. <i>Journal of Neural Transmission</i> , 2009, 116, 301-305.	1.4	41
39	Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naïve and treated schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 195-202.	1.8	80
40	The role of cannabis in cognitive functioning of patients with schizophrenia. <i>Psychopharmacology</i> , 2009, 205, 45-52.	1.5	87
41	The endocannabinoid system as a target for modelling psychosis. <i>Psychopharmacology</i> , 2009, 206, 551-561.	1.5	42
42	Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. <i>Molecular Psychiatry</i> , 2008, 13, 1118-1128.	4.1	124
43	Cannabis and psychiatric disorders: it is not only addiction. <i>Addiction Biology</i> , 2008, 13, 264-275.	1.4	179
44	High Throughput Lipidomic Profiling of Schizophrenia and Bipolar Disorder Brain Tissue Reveals Alterations of Free Fatty Acids, Phosphatidylcholines, and Ceramides. <i>Journal of Proteome Research</i> , 2008, 7, 4266-4277.	1.8	171
45	Improvement of General Symptoms in a Chronic Psychotic Patient Treated with Finasteride: Case Report. <i>Pharmacopsychiatry</i> , 2008, 41, 115-116.	1.7	19
46	Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use. <i>Schizophrenia Research</i> , 2007, 94, 29-36.	1.1	219
47	Oxcarbazepine?Efficacy and Tolerability During Treatment of Alcohol Withdrawal: A Double-Blind, Randomized, Placebo-Controlled Multicenter Pilot Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 1188-1194.	1.4	37
48	Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. <i>Journal of Neural Transmission</i> , 2007, 114, 1055-1063.	1.4	159
49	CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis. <i>PLoS ONE</i> , 2007, 2, e756.	1.1	93
50	Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. <i>Schizophrenia Research</i> , 2006, 88, 142-150.	1.1	86
51	Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia. <i>PLoS Medicine</i> , 2006, 3, e327.	3.9	242
52	Disease Biomarkers in Cerebrospinal Fluid of Patients with First-Onset Psychosis. <i>PLoS Medicine</i> , 2006, 3, e428.	3.9	159
53	Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. <i>Psychopharmacology</i> , 2005, 179, 447-451.	1.5	58
54	Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms. <i>Neuropsychopharmacology</i> , 2004, 29, 2108-2114.	2.8	423

#	ARTICLE	IF	CITATIONS
55	Antibodies to infectious agents in individuals with recent onset schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 4-8.	1.8	201
56	Oxcarbazepine as an Adjunct for Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1130-a-1131.	4.0	16
57	Cannabis, cannabinoids and bipolar disorder. , 0, , 129-136.		2